Kunming Longjin Pharmaceutical Co Ltd (002750) - Cash Flow Conversion Efficiency

Latest as of September 2023: -0.011x

Based on the latest financial reports, Kunming Longjin Pharmaceutical Co Ltd (002750) has a cash flow conversion efficiency ratio of -0.011x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-6.69 Million ≈ $-978.60K USD) by net assets (CN¥582.16 Million ≈ $85.19 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 002750 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Kunming Longjin Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)

This chart illustrates how Kunming Longjin Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Kunming Longjin Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Kunming Longjin Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Shandong Chenming Paper Holdings Limited
F:SCD1
0.823x
Gunpoint Exploration Ltd
V:GUN
-0.013x
Xreality Group Ltd
AU:XRG
0.212x
R.P.P. Infra Projects Limited
NSE:RPPINFRA
0.014x
Hudson Global Inc
NASDAQ:HSON
0.003x
Shengfeng Development Limited Class A Ordinary Shares
NASDAQ:SFWL
-0.112x
Power Solution Technologies Public Company Limited
BK:PSTC
-0.010x
PTL LTD Ordinary Shares
NASDAQ:PTLE
-0.445x

Annual Cash Flow Conversion Efficiency for Kunming Longjin Pharmaceutical Co Ltd (2011–2024)

The table below shows the annual cash flow conversion efficiency of Kunming Longjin Pharmaceutical Co Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Kunming Longjin Pharmaceutical Co Ltd stock valuation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥494.21 Million
≈ $72.32 Million
CN¥-34.24 Million
≈ $-5.01 Million
-0.069x +4.52%
2023-12-31 CN¥541.13 Million
≈ $79.18 Million
CN¥-39.26 Million
≈ $-5.75 Million
-0.073x -203.80%
2022-12-31 CN¥604.77 Million
≈ $88.50 Million
CN¥-14.44 Million
≈ $-2.11 Million
-0.024x -9.42%
2021-12-31 CN¥678.29 Million
≈ $99.26 Million
CN¥-14.80 Million
≈ $-2.17 Million
-0.022x -126.96%
2020-12-31 CN¥704.71 Million
≈ $103.12 Million
CN¥-6.78 Million
≈ $-991.68K
-0.010x -258.38%
2019-12-31 CN¥665.89 Million
≈ $97.44 Million
CN¥4.04 Million
≈ $591.66K
0.006x -87.44%
2018-12-31 CN¥655.93 Million
≈ $95.98 Million
CN¥31.70 Million
≈ $4.64 Million
0.048x -46.27%
2017-12-31 CN¥645.54 Million
≈ $94.46 Million
CN¥58.06 Million
≈ $8.50 Million
0.090x -42.15%
2016-12-31 CN¥670.46 Million
≈ $98.11 Million
CN¥104.24 Million
≈ $15.25 Million
0.155x +32.78%
2015-12-31 CN¥599.41 Million
≈ $87.71 Million
CN¥70.19 Million
≈ $10.27 Million
0.117x -52.34%
2014-12-31 CN¥285.57 Million
≈ $41.79 Million
CN¥70.16 Million
≈ $10.27 Million
0.246x -30.30%
2013-12-31 CN¥302.00 Million
≈ $44.19 Million
CN¥106.46 Million
≈ $15.58 Million
0.353x -12.24%
2012-12-31 CN¥226.94 Million
≈ $33.21 Million
CN¥91.16 Million
≈ $13.34 Million
0.402x -1.16%
2011-12-31 CN¥186.74 Million
≈ $27.33 Million
CN¥75.90 Million
≈ $11.11 Million
0.406x --

About Kunming Longjin Pharmaceutical Co Ltd

SHE:002750 China Drug Manufacturers - Specialty & Generic
Market Cap
$34.58 Million
CN¥236.29 Million CNY
Market Cap Rank
#23326 Global
#4716 in China
Share Price
CN¥0.59
Change (1 day)
+3.51%
52-Week Range
CN¥0.57 - CN¥0.61
All Time High
CN¥25.99
About

Kunming Longjin Pharmaceutical Co., Ltd. therapeutic medicines for people living with cardiovascular, cerebrovascular, and metabolic diseases in China. The company offers medicines in the areas of cardiovascular and cerebrovascular, digestive system, vitamin, minerals and enteral nutrition, and immunology, as well as first aid kits; extracts of natural plants, such as breviscapine; and industrial… Read more